Claim Missing Document
Check
Articles

Found 2 Documents
Search

The Use of Ketamine in Traumatic Brain Injury Firdaus, Riyadh; Natanegara, Ahmad Pasha; Sutedja, Anasthasia D.; Kartika, Gloria
Jurnal Neuroanestesi Indonesia Vol 14, No 1 (2025)
Publisher : https://snacc.org/wp-content/uploads/2019/fall/Intl-news3.html

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24244/jni.v14i1.633

Abstract

Ketamine, initially developed as an anesthetic agent, has gained significant attention for its potential therapeutic effects in various neurological conditions, particularly in patients with traumatic brain injury (TBI). The use of ketamine is controversial, especially due to concerns that it may increase intracranial pressure in patients with TBI. In this case report, a 29-year-old male with a diagnosis of severe head injury complicated by hemorrhagic shock from multiple traumas presented with decreased consciousness, active bleeding from the extremities, and hemodynamic instability. Rapid Sequence Intubation (RSI) was performed, during procedure which the patient was administered ketamine at a dose of 1 mg/kg, lidocaine 1.5 mg/kg, and rocuronium at 1 mg/kg. Fluid resuscitation with 1000 ml of crystalloid solution and norepinephrine drip 0.1 mcg/kg/min was also initiated. Post-resuscitation, the patient's hemodynamics were monitored and found stable. A literature search revealed systematic reviews from 2020 and studies from 2022 that focused on outcomes related to intracranial pressure and mortality in TBI patients receiving ketamine. The use of ketamine did not demonstrate evidence of harm in patients with traumatic head injury.
Caspase-3 and beclin-1 in patients with and without intra-aortic balloon pump after cardiac arrest: Study of apoptosis and autophagy Firdaus, Isman; Bunga Dewanggi; Kartika, Gloria; Andriantoro, Hananto; Yuniadi, Yoga; Boom, Cindy Elfira; Harimurti, Kuntjoro
Heart Science Journal Vol. 7 No. 3 (2026): Predicting Restenosis in Coronary Artery Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.03.11

Abstract

Background: Ischemic and reperfusion injuries occur during cardiac arrest and after successful resuscitation, potentially triggering apoptosis and autophagy, which can cause irreversible cell damage or death. Beclin-1 and Caspase-3 are proteins that play roles in autophagy and apoptosis pathways. However, it remains unclear whether the insertion of an IABP influences the serum levels of these proteins in patients with cardiac arrest and acute coronary syndrome (ACS). Objective: To investigate the Caspace-3 and Beclin-1 serum levels after Intra-Aortic Balloon Pumps (IABP) in cardiac arrest survivors with ACS. Methods: This is a single-center prospective randomized control trial (RCT) study using an unpaired t-test and a Mann-Whitney U-test to analyze the data (p-value<0.05). Result: This study included sixty subjects: 48 males and 12 females, with a mean age of 60.3 ± 9.85 years. The result showed there’s no significant difference in Beclin-1 and Caspase-3 serum levels before and after the insertion of IABP in both survival and non-survival groups (p=0.676). Caspace-3 serum level was higher in non-survival group. ROC curve analysis showed the caspase-3 level has a predictive value for mortality in cardiac arrest survivors with ACS (p=0.012). Conclusion: IABP insertion in cardiac arrest patients with ACS doesn’t significantly affect Beclin-1 and Caspase-3 levels. Caspase-3 serum levels may predict mortality in these patients, with a sensitivity of 64% and a specificity of 66.7%.